ArticleScientific reports2025
Novel model of cardiac hypertrophy with cardiorenal dysfunction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Cardiovascular diseases (CVDs) are a leading global cause of mortality. Hypertension (HTN) is a primary risk factor for developing and progressing CVDs, like cardiac hypertrophy and renal dysfunction. The use of experimental models to better understand the mechanisms linking HTN, cardiac hypertrophy, and renal dysfunction is essential. We aim to investigate whether cardiac hypertrophy induced by the aortic constriction model (TAC), combined with sodium oxalate (OXA) gavage, can serve as a novel model of cardiac hypertrophy with cardiorenal dysfunction. Four groups of C57BL/6 mice were randomized: SHAM (sham surgery and vehicle gavage), TAC (TAC surgery and vehicle gavage), OXA (sham surgery and OXA gavage), and TAC + OXA (TAC surgery and OXA gavage). In the eighth week, the TAC group exhibited elevated systolic carotid pressure, cardiac hypertrophy, increased end-diastolic volume and LV internal diameter, and renal inflammation, but did not exhibit renal dysfunction. OXA gavage intensely increased autonomic modulation as a whole (SD-PI: SHAM = 5.97 ± 1.31 vs. OXA = 15.55 ± 4.03, p < 0.01), caused an increase in the gene expression of SERCA2, changed the LV relaxation phase and induced renal injury, but did not cause an increase in carotid pressure or cardiac hypertrophy. The combination of TAC with OXA gavage in the TAC + OXA group caused increased carotid pressures, cardiac hypertrophy, pulmonary congestion, loss of baroreflex sensitivity (alpha index: SHAM = 3.64 ± 1.0 vs. TAC + OXA = 0.68 ± 0.13, p < 0.04), increased expression of SERCA2 and induced renal dysfunction. Conclusion: The combination of TAC with OXA gavage generated a novel model of cardiac hypertrophy with cardiorenal dysfunction, with a greater state of cardiac decompensation than when TAC and OXA are used separately, and caused significant renal dysfunction, a situation not observed in the TAC model or the OXA gavage model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.